| Original language | English (US) |
|---|---|
| Pages (from-to) | 1260-1274 |
| Number of pages | 15 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 130 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2012 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Standardizing double-blind, placebo-controlled oral food challenges : American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. / Sampson, Hugh A.; Gerth Van Wijk, Roy; Bindslev-Jensen, Carsten et al.
In: Journal of Allergy and Clinical Immunology, Vol. 130, No. 6, 12.2012, p. 1260-1274.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Standardizing double-blind, placebo-controlled oral food challenges
T2 - American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report
AU - Sampson, Hugh A.
AU - Gerth Van Wijk, Roy
AU - Bindslev-Jensen, Carsten
AU - Sicherer, Scott
AU - Teuber, Suzanne S.
AU - Burks, A. Wesley
AU - Dubois, Anthony E.J.
AU - Beyer, Kirsten
AU - Eigenmann, Philippe A.
AU - Spergel, Jonathan M.
AU - Werfel, Thomas
AU - Chinchilli, Vernon M.
N1 - Funding Information: Disclosure of potential conflict of interest: H. A. Sampson is on the Danone Scientific Advisory Board; has received consultancy fees from Allertein Therapeutics and the Food Allergy Initiative (FAI); is employed by Mount Sinai Medical School; has received research support from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) ; has received royalties from Elsevier-Wiley and UpToDate; has received travel expenses from the NIAID; and is 42.5% shareholder of Herbs Springs, LLC. R. Gerth van Wijk has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI) ; is on the board for the World Allergy Organization and EAACI; has received consultancy fees from MSD, Crucell, and Haarlems Allergenen Lab; is employed by Erasmus Medical Center; has received research support from Zon-MW , STW , and Biomay ; has received lecture fees from Allergopharma; and receives royalties from Handboek Allergologie, Het Allergie Formulatius, and Het Allergie Boek. C. Bindslev-Jensen has received lecture fees from MSD and Thermo-Fisher. S. Sicherer has received consultancy fees from the FAI. S. S. Teuber has consulted for Sanofi-Aventis. A. W. Burks has received grants and support for travel from the NIH/NIAID; is on boards for the NIH HAI, US Food and Drug Administration (FDA), and American Academy of Allergy, Asthma & Immunology (AAAAI); has consulted for Dannon Company, Merck & Co, Exploramed Development Intelliject, McNeil Nutritionals, Novartis Pharma AG, and Schering-Plough; has received grants from the Food Allergy & Anaphylaxis Network , the FAI , the NIH, and Wallace Research Foundation ; has received royalties from UptoDate; has received payment for educational presentations from Current Views; and owns stock or stock options in Allertein and MastCell Pharmaceuticals. A. Dubois has received travel and hotel costs from the EAACI, is on the ALK-Abelló Adrenaline Board, and has received research support from ALK-Abelló . K. Beyer has received consultancy fees from Danone, Novartis, and ALK-Abelló; has received research support from the German Research Foundation , European Union , Danone , and Foundation of the Treatment of Peanut Allergy ; and has received lecture fees from Danone, Phadia, Infectopharm, CSL Behring, Novartis, UCB, Meda Pharma, and Med Update. P. A. Eigenmann has received travel support from the EACCI; has consulted for DBV Technologies, Danone, Nestlé, and ALK-Abelló; has received grants from LETI and Nestlé ; has received payment for lectures from Stallergenes, Sodilac, and Phadia; has received royalties from UpToDate and Elsevier; and owns stock or stock options in DBV Technologies. J. M. Spergel is on the advisory board for and has stock/stock options in DBV; has received consultancy fees from Danone; has received research support from the Department of Defense, Ception, NIH, and Nutricia ; has received lecture fees from Abbott and Nutricia; receives royalties from UpToDate; and has received payment for development of educational presentations from MEI. T. Werfel has received travel support from the EAACI. V. M. Chinchilli has received travel support from the AAAAI.
PY - 2012/12
Y1 - 2012/12
UR - http://www.scopus.com/inward/record.url?scp=84870260207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870260207&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2012.10.017
DO - 10.1016/j.jaci.2012.10.017
M3 - Article
C2 - 23195525
AN - SCOPUS:84870260207
SN - 0091-6749
VL - 130
SP - 1260
EP - 1274
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -